Artelo Biosciences receives Nasdaq delisting notice for bid price non-compliance; changes fiscal year end

ARTELO BIOSCIENCES, INC.

Received Nasdaq notice on Sept 13, 2021 for failure to meet $1.00 minimum bid price (Listing Rule 5550(a)(2)).
Has 180 days until March 14, 2022 to regain compliance by closing bid price >= $1.00 for 10 consecutive business days.
Possible second 180-day cure period if other standards met; otherwise delisting with appeal rights.
Board resolved on Sept 17, 2021 to change fiscal year end from Aug 31 to Dec 31, effective Jan 1, 2022.
No immediate effect on listing; company will monitor price and consider options.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.